Nef-mediated enhancement of cellular activation and human immunodeficiency virus type 1 replication in primary T cells is dependent on association with p21-activated kinase 2
© Olivieri et al; licensee BioMed Central Ltd. 2011
Received: 17 December 2010
Accepted: 5 August 2011
Published: 5 August 2011
The HIV-1 accessory protein Nef is an important determinant of lentiviral pathogenicity that contributes to disease progression by enhancing viral replication and other poorly understood mechanisms. Nef mediates diverse functions including downmodulation of cell surface CD4 and MHC Class I, enhancement of viral infectivity, and enhancement of T cell activation. Nef interacts with a multiprotein signaling complex that includes Src family kinases, Vav1, CDC42, and activated PAK2 (p21-activated kinase 2). Although previous studies have attempted to identify a biological role for the Nef-PAK2 signaling complex, the importance of this complex and its constituent proteins in Nef function remains unclear.
Here, we show that Nef mutants defective for PAK2-association, but functional for CD4 and MHC Class I downmodulation and infectivity enhancement, are also defective for the ability to enhance viral replication in primary T cells that are infected and subsequently activated by sub-maximal stimuli (1 μg/ml PHA-P). In contrast, these Nef mutants had little or no effect on HIV-1 replication in T cells activated by stronger stimuli (2 μg/ml PHA-P or anti-CD3/CD28-coated beads). Viruses bearing wild-type Nefs, but not Nef mutants defective for PAK2 association, enhanced NFAT and IL2 receptor promoter activity in Jurkat cells. Moreover, expression of wild-type Nefs, but not mutant Nefs defective for PAK2 association, was sufficient to enhance responsiveness of primary CD4 and CD8 T cells to activating stimuli in Nef-expressing and bystander cells. siRNA knockdown of PAK2 in Jurkat cells reduced NFAT activation induced by anti-CD3/CD28 stimulation both in the presence and absence of Nef, and expression of a PAK2 dominant mutant inhibited Nef-mediated enhancement of CD25 expression.
Nef-mediated enhancement of cellular activation and viral replication in primary T cells is dependent on PAK2 and on the strength of the activating stimuli, and correlates with the ability of Nef to associate with PAK2. PAK2 is likely to play a role in Nef-mediated enhancement of viral replication and immune activation in vivo.
The HIV-1 accessory protein Nef is an important determinant of lentiviral pathogenicity (reviewed in ). Infections with Nef-deleted strains of HIV-1 [2, 3] or SIVmac [4, 5] result in limited disease progression in humans and primates, respectively. The mechanisms by which Nef enhances viral replication and pathogenicity are unclear. A conserved feature of lentiviral nef genes is the ability to enhance viral replication in freshly isolated T cells that are infected and subsequently activated 2 to 5 days post-infection [6–11]. Under these conditions, Nef+ viruses replicate with faster kinetics and peak at higher levels (approximately 10-fold) than Nef- viruses. In contrast, Nef has little or no effect on viral replication when T cells are activated prior to infection . In addition to enhancing viral replication in freshly isolated T cells, Nef mediates downregulation of cell surface receptors via interaction with the endocytic machinery. Downmodulation of cell surface CD4 reduces interference with viral envelope protein function [12, 13]. Nef also downmodulates MHC Class I, which protects infected cells from CTL-mediated lysis [14, 15]. Thus, Nef-mediated effects on viral replication and pathogenesis may depend in part on its ability to enhance viral replication in resting CD4+ T cells.
In resting T cells, HIV-1 viral replication is blocked at a step prior to integration . This restriction is overcome when resting T cells are activated in response to TCR stimulation [16–18]. Nef, which is expressed early after infection in resting T cells , increases the number of T cells that activate NFAT and NF-κB promoter elements [20–23], secrete IL-2 , and express activation markers such as CD25  and CD69  in response to TCR stimulation. Nef appears to lower the threshold required for T cell activation, which may increase the permissiveness of cells for productive infection.
Previous studies suggest that Nef lowers the activation threshold by interacting with components of the T cell signaling machinery. Nef, via its SH3-binding P72xxP75 motif, associates with the Src Family kinases (SFKs) Fyn  and Lck [28, 29], which are proximal signaling molecules activated immediately after TCR stimulation . Nef also modulates the activation of downstream effectors important for activation-induced cytoskeletal rearrangement including PAK2, CDC42, Vav [31, 32], WASP (Wiscott-Aldrich Syndrome protein) , and the Ezrin Radixin Moesin (ERM) proteins Merlin  and cofilin [35, 36]. Nef associates with an activated form of PAK2 [37–39], a serine/threonine kinase important in T cell activation and stress responses, in a multiprotein complex found in detergent insoluble lipid rafts [40, 41]. This association is dependent on both CDC42 and Vav1 and, possibly, β-PIX [42, 43]. Functional links between SFKs and PAK2 through Vav1 and CDC42 suggest Nef-PAK2 association may serve as a marker for a Nef-multiprotein signaling complex capable of altering T cell responsiveness via interaction with multiple host cell factors. Despite extensive characterization of the molecular determinants of Nef-PAK2 association, the importance of this association for Nef function is still unclear.
The P72xxP75 motif of Nef is important for PAK2 and SFK-association and contributes to MHC Class I downmodulation [44, 45]. Mutation of this motif also abrogates Nef-mediated enhancement of HIV-1 replication [46, 47] and T cell activation . It is therefore difficult to distinguish requirements for PAK2-association, SFK-association, and MHC Class I downmodulation in Nef-mediated enhancement of replication and T cell activation. We previously indentified residues important for PAK2 association, but dispensable for CD4 or MHC Class I downmodulation [48–50]. These determinants of PAK2 association are located in a hydrophobic binding surface formed by Clade B consensus positions 85, 89, 90, 186,187,188, and 191 . Mutation of residue 191, however, disrupts Nef association with Vav  and SFKs . Mutations at position 191 (F191H and F191R) do not abrogate Nef-mediated enhancement of NFAT activity in cells stimulated for 18 h with 1 μg/ml PHA-P . However, these mutants are unlikely to be completely null for PAK2-association . The role of Nef-PAK2 association in Nef-mediated enhancement of T cell activation and viral replication under various levels of cell stimulation remains to be determined. Therefore, further analyses of Nef variants bearing mutations in the hydrophobic binding surface may provide insight into the biological role of the Nef-PAK2 complex in Nef-mediated enhancement of viral replication and T cell activation.
Here, we demonstrate that HIV-1 Nef mutants defective for the ability to associate with PAK2 are also defective for the ability to enhance viral replication in freshly isolated primary T cells that are infected and subsequently activated by sub-maximal stimuli. Furthermore, these Nef mutants are defective for the ability to enhance responsiveness of Nef-expressing and bystander primary T cells to activation induced by sub-maximal stimuli. siRNA knockdown of PAK2 inhibited NFAT activation both in the presence and absence of Nef, and expression of a dominant-negative PAK2 mutant abrogated Nef-mediated enhancement of CD25 expression in Jurkat cells. These findings suggest a model in which Nef interacts with PAK2 to enhance the responsiveness of infected cells and bystander cells to activating stimuli. Thus, PAK2 is likely to be important for Nef-mediated enhancement of viral replication and immune activation in vivo.
Nef association with activated PAK2 is not important for enhancement of viral infectivity
Nef enhances virion infectivity in single round infection assays, even when the virus is produced in CD4-negative cells . Contradictory data exist regarding whether or not abrogating the ability of Nef to associate with PAK2 affects virion infectivity [52, 57]. To determine if Nef proteins defective for PAK2-assocation display reduced enhancement of infectivity during a single round of replication, we infected CD4+ CXCR4+MAGI cells, which express β-galactosidase under the control of the LTR, with equal amounts of virus normalized by RT activity. At 36 h post-infection, SF2 Nef, 5C, 5C-3, 6I, and 6I-1 viruses were 3- to 4-fold more infectious than the ΔNef and 5C-A72xxA75 viruses (Figure 1C). To achieve an equal MOI, a second infection was performed with 5-fold more RT units of the ΔNef or 5C-AxxA virus (Figure 1C and 1D). This dose resulted in equivalent infectivity between ΔNef virus and the initial dose of the SF2 Nef virus (Student's t test p = 0.7), or between 5C-AxxA virus and the initial dose of 5C virus (p = 0.5). Equivalent MOIs were therefore achieved using equal RT units of wild type and mutant Nef bearing virus and 5-fold more RT units of the ΔNef or 5C-AxxA virus. These data indicate that PAK2 association is not important for Nef-mediated enhancement of infectivity during a single round of viral replication.
Nef-mediated enhancement of viral replication is highly dependent on the strength of activating stimuli
To examine whether Nef-PAK2 association is important for Nef-mediated enhancement of viral replication in primary T cells, we then tested a panel of viruses for their ability to replicate in freshly isolated PBMC under each of the conditions described above. We used each of these stimuli in the presence of IL-2 to activate freshly isolated PBMC that were previously infected with an equivalent infectious dose of virus. Viral replication was monitored by p24 ELISA of culture supernatants. In cultures stimulated with α-CD3/CD28 beads, viruses expressing Nef proteins capable of associating with activated PAK2 (SF2, 5C, and 6I-1) replicated at similar levels compared to viruses expressing Nef proteins defective for PAK2 association (5C-3, 5C-AxxA, and 6I) or ΔNef virus (Figure 2B). At this strong level of stimulation, there was no difference in levels of Nef+ and Nef- HIV-1 replication. When cultures were stimulated with 2 μg/ml PHA-P, ΔNef virus replicated more slowly than SF2 Nef virus, achieving peak levels of viral replication 3 days later. Under this condition, wild-type virus replicated to peak values that were 3-fold lower compared to those seen when cultures were stimulated with α-CD3/CD28 beads, and the 5C-AxxA virus replicated to 2-fold lower peak values compared to the 5C and 5C-3 viruses. No difference was observed between the 5C and 5C-3 viruses, or the 6I-1 and 6I viruses. At this intermediate level of stimulation, differences between Nef+ and Nef- viruses were detected but Nef-mediated enhancement of viral replication was considerably less than the 10-fold effect previously reported [7, 9]. When 1 μg/ml PHA-P was used, wild-type virus replicated to a peak value 3-fold lower than the levels observed when 2 μg/ml PHA-P was used as a stimulus. Under this condition, the ΔNef virus failed to replicate to detectable levels (Figure 2B). CD25 MFI correlated positively with peak p24 levels of wild-type SF2 virus (Additional File 1, Figure S1A, p = 0.015, r = 0.898; Spearman correlation), and negatively with Nef-mediated enhancement of replication (Additional File 2, Figure S1B, p = 0.016, r = -0.892). In contrast, HLA-DR MFI did not correlate with viral replication (p = 0.44) or Nef-mediated enhancement of replication (p = 0.67). Therefore, increased CD25 MFI after 3 days of stimulation, rather than the % of CD25+ cells, was the best predictor of peak levels of viral replication and the ability of Nef to enhance viral replication.
The ability of Nef to associate with activated PAK2 correlates with the ability to enhance HIV-1 replication in freshly isolated PBMC
The low level of activation following stimulation with 1 μg/ml PHA-P (Figure 2B) provides an optimal window to detect Nef-mediated enhancement of HIV-1 replication in freshly isolated PBMC. Under these experimental conditions, the 5C virus replicated to peak levels ~5-fold higher than the 5C-3 and 5C-AxxA viruses. Similarly, the 6I-1 virus replicated to peak levels 3-fold higher than 6I and achieved peak levels of replication 3 days earlier. Reduced replication of the 5C-AxxA virus is consistent with previous studies . 5C-3 and 6I mutant viruses, which are defective for PAK2-association, but functional for CD4 and MHC Class I down modulation and infectivity enhancement, did not enhance replication compared to ΔNef virus. These results suggest that Nef-PAK2 association is important for enhancing HIV-1 replication when freshly isolated T cells are infected and sub-maximally activated.
Nef residues important for PAK2-association are also important for enhancing T cell activation
To determine whether Nef-PAK2 association is important for Nef-mediated enhancement of T cell activation, we infected the NFAT-Luc and IL2R-Luc reporter cells with an equal MOI of VSV-G pseudotyped virus. At 24 h post-infection, luciferase activities in unstimulated cells were equivalent between mock-infected and HIV-infected cultures irrespective of the Nef variant expressed. After 4 h of stimulation with α-CD3/CD28-coated beads, in contrast to the 72 h stimulation in Figure 2B, NFAT-Luc cells infected with SF2, 5C, and 6I-1 virus had 5-, 3.5-, and 4-fold higher levels of luciferase activity than did ΔNef, 5C-3, and 6I-1, respectively. In IL2R-Luc cells, SF2, 5C, and 6I-1 Nef had 2-, 2.5-, and 2-fold higher levels of luciferase activity than did ΔNef, 5C-3, and 6I-1, respectively (Figure 3B and 3C). After 8 h or 16 h of stimulation with α-CD3/CD28-coated beads, wild-type Nef virus did not enhance cellular activation or NFAT-luc activity compared to Nef- or mutant Nef virus unless the bead concentration was reduced (Additional File 2, Figure S2 and Additional File 3, Figure S3). Therefore, in the context of viral infection, the ability of Nef to enhance NFAT and IL2 receptor promoter-driven luciferase activity following T cell receptor stimulation correlates with its ability to associate with activated PAK2 and to enhance viral replication, and is dependent on the strength of the activating stimulus and the length of time the stimulus is applied.
Nef residues important for PAK2-association are important for enhancing activation of primary CD4 and CD8 T cells when Nef is expressed in the absence of other viral proteins
T cell activation is dependent on PAK2 both in the presence and absence of Nef
Here, we show that the ability of Nef to associate with activated PAK2 is important for its ability to enhance HIV replication in freshly isolated T cells. Mutations at positions 89 and 191, which disrupt PAK2 association, rendered Nef defective for the ability to enhance cellular activation and viral replication in freshly isolated T cells, but not the ability to enhance viral infectivity or downmodulate CD4 and MHC Class I . As expected and consistent with other reports [62, 63], by targeted siRNA knockdown we show that PAK2 is important not only for Nef-mediated enhancement of T cell activation but also for activation of T cells in the absence of Nef (Figure 5). We also show that Nef-mediated enhancement of T cell activation is abrogated in the presence of a dominant negative PAK2 mutant (Figure 6). The ability of wild-type or mutant Nefs to enhance T cell activation correlated with their ability to associate with PAK2 in co-precipitation assays in Jurkat and 293T cells (Figure 6A and 7). Together, these data are consistent with a model in which enhancement of T cell activation and HIV replication occur through related mechanisms involving Nef association with PAK2, most likely within a multiprotein complex.
Previous studies suggest that Nef enhances HIV replication by reducing the threshold of cellular activation [19, 24]. Consistent with this model, we found that Nef-dependent enhancement of viral replication in T cells stimulated after infection is highly dependent on the strength of activating stimuli. The greatest differences in levels of replication between Nef+ and Nef- viruses were observed in cultures sub-maximally stimulated with 1 μg/ml PHA-P for 72 h (Figure 2A). The strength of the activating stimulus correlated inversely with Nef-mediated enhancement of HIV-1 replication (Additional File 1, Figure S1). Reducing the concentration of α-CD3/CD28 beads (Additional File 2, Figure S2), or shortening the duration of stimulation (Additional File 3, Figure S3 and Figure 3, Figure 4, and ), is required to detect Nef-mediated enhancement of cellular activation. These findings imply that sub-maximal stimulation, regardless of whether PHA-P or α-CD3/CD28 beads are used, is required to detect Nef-mediated enhancement of viral replication and T cell activation. Excluding IL-2 from the cell culture media resulted in only 1.6% viable cells. Thus, we cannot exclude the possibility that IL-2 alone increased the number of cells permissive for infection . Importantly, these findings demonstrate that Nef-mediated enhancement of replication and activation can be masked when strong stimuli are used to induce cellular activation.
Nef may enhance HIV replication via several distinct mechanisms that are not mutually exclusive. Nef enhances viral replication in freshly isolated PBMC, which contains a small fraction of activated or partially activated T cells [6, 7, 9]. Nef expression can enhance the promoter activity of the LTR  and specific host cell genes [24, 59, 65] via mechanisms that may involve upregulation of tat-SF1, U1 SNRNP, and IRF-2 mRNAs  and enhancement of NFAT activity [20, 23], thereby increasing the amount of viral particles produced per cell. As we and others have demonstrated, Nef interaction with cell signaling machinery in unstimulated T cells may render them permissive for high levels of productive infection upon subsequent stimulation by reducing the threshold required for cellular activation. As such, the inverse correlation between Nef-mediated enhancement of replication and the strength of cellular stimulation (Additional File 1, Figure S1B) is likely to reflect both an increase in the number of permissive cells and increased p24 production per cell. We found that activation of bystander CD4 and CD8 T cells is enhanced in the presence of Nef expression cells. Bystander activation may be important for HIV replication in vivo, as this would be expected to increase the pool of target cells permissive for productive infection and to contribute to activation induced cell death of CD4 and CD8 T cells associated with HIV infection. Therefore, Nef-mediated enhancement of T cell activation may positively influence viral replication and pathogenesis via several distinct mechanisms.
The role of PAK2 in Nef-mediated enhancement of T cell activation is unclear because PAK2 activation is dependent on several cellular factors. The results of experiments using PAK2 siRNA knock-down and a dominant negative PAK2 mutant (Figure 5 and 6) imply that PAK2 itself, and/or molecules that interact with PAK2, are important for Nef-mediated enhancement of T cell activation. For example, activation of PAK2 is dependent on binding of CDC42-GTP to the PAK2 CRIB (Cdc42- and Rac-interactive binding) domain. CDC42 binds PAK2 only in its GTP bound state, which occurs after guanine nucleotide exchange factors (GEF), such as Vav, induce exchange of GDP for GTP. Nef may therefore interact with upstream signaling molecules such as SFKs, Vav1, or CDC42 in order to associate with activated PAK2. Identifying binding partners of Nef important for PAK2-association may help to identify other host cell factors necessary for Nef-mediated enhancement of T cell activation and viral replication.
Previous reports evaluating the contribution of Nef-PAK2 association to HIV replication reached conclusions that differ from our own. One study demonstrated that siRNA knockdown of PAK2 was not important for infection of HeLa and Jurkat cells . However, freshly isolated then activated primary T cells are a more relevant cell-type for studies of Nef function. Furthermore, HeLa and Jurkat cells do not require activation by external stimuli to become permissive for HIV replication. A second study used experimental conditions that may mask Nef-mediated enhancement of T cell activation . Schindler et al.  incubated Jurkat NFAT-Luc reporter cells with PHA for 16 h. However, we found that extending the time of stimulation with α-CD3/CD28 coated beads from 4 to 8 h abrogated Nef-mediated enhancement of NFAT-Luc activity (Figure 3 and Additional File 3, Figure S3) and extending the time of stimulation with 1 μg/ml PHA-P from 18 to 24 h abrogated Nef-mediated enhancement of CD25 upregulation in Jurkat E6.1 cells (Additional File 4, Figure S4). Thus, our identification of specific assay conditions in which Nef expression enhances T cell activation and HIV replication sheds light on potential explanations for different results among studies that examined the importance of PAK2 for Nef-mediated enhancement of HIV replication.
Significant controversy surrounds the issue of whether or not Nef-PAK2 association contributes to SIV pathogenesis. In two studies, rhesus macaques infected with SIV mutated in the PxxP domain of Nef did not develop high viral loads until reversion of the mutations occurred [45, 67]. In contrast, one study demonstrated that SIVmac239 containing the same PxxP mutation began to develop high viral loads 4 days prior to detection of reversion to wild-type . The inconsistency of these findings may relate to certain limitations of the SIV model. Because of rapid disease progression, SIVmac239 infection of macaques may not be an accurate model for the chronic phase of HIV infection. PAK2 activation may be more important during chronic infection, when immune activation is lower and infected T cells are more likely to be resting, than during acute infection and late stage disease, when T cells have higher levels of activation. Indeed, lymphoid-derived Nefs in late stages of disease acquire rare, non-conservative mutations at positions critical for PAK2-association potentially abrogating the ability of Nef to associate with PAK2 . Accordingly, Nef-PAK2 association may be important for pathogenesis in vivo in the same context for which it is important for enhancing replication in vitro: when infected T cells are resting.
An important finding in our study relates to technical issues that may help to explain major discrepancies between results from different groups regarding HIV replication in freshly isolated PBMC. Three technical points were critical for reproducibility of a strong Nef-dependent phenotype in freshly isolated PBMC: 1) using PBMC isolated from fresh blood instead of cryopreserved PBMC; 2) using highly purified PBMC free of platelet contamination; and 3) using pooled human A/B serum determined to be free of endotoxin. Our preliminary studies comparing different methods for this assay suggested that PBMC derived from cryopreserved rather than fresh samples, as well as PBMC containing even low levels of contaminating platelets, are more "activated" than PBMC obtained from fresh blood or isolated free of platelet contamination. Thus, assays that use cryopreserved PBMC or are conducted in the presence of contaminating platelets are not representative of results in "resting" PBMC. Platelets can release RANTES and other soluble factors that can activate PBMC, so platelet-free PBMC preparations are critical for assays that depend on a "resting" PBMC phenotype. We observed that fetal bovine serum (FBS) enhances survival of activated PBMC compared to pooled human A/B serum, thereby increasing the number of activated cells and reducing the percentage of resting cells. Thus, stimulation in the presence of FBS may result in stronger cell stimulation than delivering the same stimulus in the presence of human A/B serum. We have shown that the ability of Nef to enhance replication in freshly isolated PBMC is highly dependent on the strength and duration of stimulation. Therefore, confounding factors that enhance the strength of stimulation may mask certain Nef phenotypes. For example, the presence of endotoxin in some serum preparations may alter the cytokine profile of PBMC. In summary, using freshly isolated rather than cryopreserved PBMC and reducing PBMC activation by factors such as platelet contamination and serum endotoxin, and determining the strength and duration of stimulation required for sub-maximal stimulation are critical in order to achieve consistent effects of Nef on HIV-1 replication in resting T cells from a given donor.
HIV-1 Nef-mediated enhancement of T cell activation and viral replication in T cells is dependent on PAK2 and the strength of T cell activating stimuli, and correlates with the ability of Nef to associate with PAK2. Nef-mediated enhancement of T cell activation may increase the number of infected cells able to produce progeny virus along with the amount of virus produced per cell. Additionally, Nef increases the number of uninfected bystander cells permissive for viral replication in a manner that is dependent on Nef residues important for PAK2 association. Two structural domains appear to govern the ability of Nef to enhance activation of infected and uninfected cells: the PxxP motif, which interacts with SH3 domains, and the hydrophobic binding surface formed between residues 89 and 191, which may interact with an unknown binding partner . Future analysis of the Nef-PAK2 interaction will examine the ability of Nef to associate with SH3 domain-containing cellular factors that influence both PAK2 association and T cell activation. This interaction is an attractive potential therapeutic target because an inhibitor that blocks the ability of Nef to interact with host cell factors important for enhancement of HIV-1 replication and T cell activation would be expected to reduce viral replication and, similar to infections with Nef-deleted strains of HIV and SIV, postpone the onset of AIDS.
Materials and methods
Primary Nefs and their mutants cloned into pCR3.1 were digested with BamHI and ClaI and inserted into the corresponding sites in a modified pNL4-3 provirus . SF2 Nef was inserted via MluI and ClaI sites. Nef-negative pNL4-3 ΔXhoI was provided by Damian Purcell. Viral stocks were produced by CaPO4 transfection of 3 × 106 293T cells in a 10 cm plate with 10 ug of provirus and, where indicated, 1 ug of pVSV-G. Viral stocks were assayed for reverse transcriptase activity as described previously .
Lentiviral Vector Construction and Production
pCR3.1 Nef plasmids were amplified with primers 5'AAAAGCGGCCGCCACCATGGGTGGCAAGTGGTCAAAA3' and 5'AAGGATCCTCATGAAGCGTAATCTGGCAC 3', which add a NotI site and a Kozak sequence to the 5' end of Nef and a BamHI site to the 3' end of Nef. Nef genes were inserted into pHAGE fEF1α-IRES-zsGreen which was kindly provided by the Harvard Gene Therapy Initiative . 3.5 μg of pHAGE vector,3.5 μg of the packaging construct pDR89.1 , and 1 μg of pVSV-G were transfected by lipid transfection (LipoD293T, Signagen) into 5.5 × 106 293T cells plated 24 h prior in a 10-cm tissue culture plate. Medium was changed at 18 h and vector containing supernatants were harvested after an additional 24 hours. Vector containing supernatants were assayed for RT activity as described previously .
PBMC Isolation and Infection
Healthy HIV-/HCV- donor blood provided by Research Blood Components (Boston, MA) was collected into EDTA vacutainer tubes. The protocol for obtaining blood was approved by the Dana-Farber Cancer Institute IRB. After collection, 10 mls of fresh blood were diluted 1:1 with PBS and layered over 15 ml Ficoll Histopaque 1077 (Sigma) and spun at 2000 × g for 20 min at room temperature. 5 mls of PBMC containing serum were collected at the interface and diluted with 20 mls of PBS. The diluted cells were pelleted at 1000 × g for 10 min at 4°C, resuspended in 10 mls of PBS, and pelleted again at 1000 × g for 10 min. The cell pellet was resuspended in 10 mls of RPMI-1640 (Invitrogen) and pelleted at 1000 × g for 10 min. Cells were counted and resuspended at 2 × 106/ml in RPMI-1640 with 10% pooled Human A/B sera (Gemini) and 5 U/ml penicillin/streptomycin. Infections contained 8 X105 cells in 800 μl with 4,000 3H cpm of RT activity for SF2, 5C, 5C-3, 6I-1, and 6I Nef-bearing proviruses or 12,000 and 16,000 3H cpm of RT activity for pNL4-3 ΔXhoI and 5C-AxxA, respectively. Freshly-isolated PBMC were incubated overnight in a 15 ml conical tube at 37°C and washed twice in PBS the following day. Cells were resuspended in 800 μl of media and incubated for 2 days. On day 3 post-infection, cells were pelleted and resuspended in media containing 10 u/ml IL-2 with either 1 ug/ml PHA-P (Sigma), 2 ug/ml PHA-P, or α-CD3/CD28 beads (Invitrogen) at a bead-to-cell ratio of 1:1. Three days post-activation (day 6 post-infection), infected cultures were washed twice and returned to media containing 10 u/ml IL-2. Replicate samples of activated PBMC were analyzed for levels of cell activation as described below. Two hundred μl of resuspended cultures were plated in triplicate in a 96-well U-bottom plate. Every three or four days, 0.5 volume of media was removed and saved, and replaced with 0.5 volume fresh media to compensate for evaporation. Viral replication was measured by p24 ELISA (Perkin-Elmer) of culture supernatants.
2 × 105 PBMC were washed twice with cold PBS containing 2 mM EDTA (PBS-E) and resuspended in 200 μl of PBS-E containing 2% FBS with 5 μl of CD3-FITC (BD Pharmingen) and 5 μl of CD25-PE (BD Pharmingen). Cells and antibody were incubated at 4°C for 45 min. Cells were washed twice with PBS-E and resuspended in PBS and analyzed on a BD FACSCanto II cell cytometer. FACS analysis was done using BD FACSDiva software.
4 × 104 MAGI indicator cells (NIH AIDS Reagent Repository) were plated in a 12-well plate in selection media (Dulbecco's modified Eagle's medium (DMEM; Invitrogen) supplemented with 10% fetal calf serum, 5 U/ml pen/strep plus 0.2 mg/ml G418 (at an active concentration of 700 μg per mg), 50 U/ml hygromycin, and 1 μg/ml puromycin. Twenty-four hours later, selective media was removed from three wells at a time and replaced with 5000 cpm of RT activity in 300 μl of DMEM plus 20 μg/ml of DEAE-Dextran. Cells and virus were incubated for 6 h at 37°C. Cells were washed three times with PBS and incubated for 36 h at 37°C in 1 ml of DMEM without selection. Cells were washed once and fixed with 1 ml of 1% formaldehyde, 0.2% glutaraldehyde in PBS for 5 min. The cells were washed twice with PBS and incubated with PBS containing 4 mM potassium ferrocyanide, 4 mM potassium fericcyanide, 2 mM Mg2Cl, and 0.4 mg/ml X-gal for 50 min at 37°C in a dry incubator. Three random fields from each of three triplicate wells were counted for each infection. Percent Infected cells = β-galactosidase + cells (blue cells) in field/total number of cells in field × 100%.
Luciferase Reporter Assay
IL2R-Luc and NFAT-Luc Jurkat E6.1 cells were kindly provided by Dr. Michel Tremblay, University of Laval, Montreal, Canada . 5 × 105 cells were plated in 1 ml of non-selective media with 200,000 cpm of RT of VSV-G pseudotyped vectors and incubated for 18 h. Cells were washed twice with PBS and resuspended in 1 ml of media containing 5 × 105 α-CD3/CD28 beads (Invitrogen). After 6 h of incubation at 37°C, the cells were pelleted, washed twice with PBS and resuspended in 200 μl Passive Lysis Buffer (Stratagene), incubated at room temperature for 15 min, and subjected to one round of freeze/thaw. Twenty μl of lysate was added to wells of a 96-well white-wall black plate. 100 μl Stratagene Luciferase Assay buffer mixture was added and luciferase activity was read on a Bethold Centro LB 960 luminometer.
2 × 106 freshly-isolated PBMC were incubated in 1 ml of media containing 750,000 3H cpm of RT activity in the presence of 8 μg/ml polybrene. Cells were spun for 2 h at 2,000 RPM at 30°C, incubated overnight. Media was removed and 10% glycerol in PBS solution was added and immediately washed twice with PBS. 2 × 105 cells were added to a U-bottom, 96-well plate in media containing 10 U/ml IL-2 for three days. Fresh media containing 1 μg/ml PHA-P and 10 U/ml IL-2 or IL-2 alone were added to the cultures and incubated for 72 h. Cells were then washed twice with cold PBS-E and resuspended in 200 μl PBS-E FBS containing 1 μl of CD25-APC-Cy7 (BD Pharmingen), 5 μl CD8-PE, and 5 μl CD3-PE Cy5.5. Cells were incubated for 45 min at 4°C, washed twice with PBS-E, and resuspended in PBS. Acquisition and analysis were done with a BD FACSCanto cell cytometer using BD FACSDiva software. FSC and SSC were used to define a lymphocyte population consistent between all samples.
siRNA transfection of Jurkat E6.1 cells
5 × 106 Jurkat E6.1 cells were nucleofected in 100 μl AMAXA Solution V in program S-18 with 10 or 2 pmol of siRNA targeting PAK2 (SmartPool, Dharmacon) or non-targeting control siRNA (Dharmacon). Cells were cultured for 48 h in 10% FBS RPMI supplemented with 1X GlutaMax (Invitrogen), prior to infection or 66 h prior to SDS-PAGE/Western blot analysis for PAK2 expression. SDS-PAGE/Western blotting was carried out as described above. Blots were probed with anti-β-tubulin (1:1000, Sigma-Aldrich) and rabbit anti-PAK2 (1:1000, Cell Signaling).
Generation of Jurkat cells stably expressing a dominant negative PAK2 mutant
106 Jurkat E6.1 cells were nucleofected in 100 μl AMAXA Solution V in program S-18 with 1 μg of pCDNA3.1FLAG-PAK2 K278R. Cells were passaged in 1 mg/ml G418 10% FBS RPMI supplemented with 1X GlutaMax (Invitrogen) for 15 days. Expression of the FLAG-tagged PAK2 mutant was confirmed by Western blot with anti-FLAG. 3 × 106 parental control or PAK2 DN-expressing Jurkat E6.1 cells were transduced with 25,000 cpm of RT activity of pHAGE-Nef-IRES-zsGreen vectors. 8 h post-transduction, cells were washed twice and stimulated with 1 μg/ml PHA-P for 18 h, following which cells were stained with CD25 APC-Cy7 and analyzed by flow cytometry for zsGreen and CD25 expression.
Nef-PAK2 co-immunoprecipitation in Jurkat E6.1 PAK2 DN cells
3 × 106 Jurkat E6.1 parental or Jurkat E6.1 PAK2 DN cells were transduced with 600,000 cpm of RT activity of VSV-G pseudotyped pHAGE Nef-IRES-zsGreen vectors. Cells were incubated for 16 h with lentiviral vectors and then washed twice with PBS. After 48 h in culture, cells were washed twice with PBS and lysed in 1 ml 1% NP-40 lysis buffer. Immunocomplexes were isolated and analyzed as described below.
Nef-PAK2 co-immunoprecipitation in 293T cells
4.5 × 105 293T cells were seeded into 6-well plates 24 h prior to transfection. 0.5 μg pCR3.1 Nef-HA or empty vector, 0.5 μg pCDNA.31 FLAG-PAK2 K278R, and 0.5 μg CDC42 V12 in 75 μl serum-free DMEM were mixed with 3 ul GenJet (SignaGen) in 75 μl serum-free DMEM, incubated for 15 minutes, and added to culture wells. 48 h post-transfection, cells were washed twice with PBS and lysed in 1 ml 1% NP-40, 50 mM Tris, 150 mM NaCl, pH 8.0 lysis buffer containing Compete Protease Inhibitor (Roche) and PhosphoStop phosphatase inhibitor (Roche). Insoluble material was pelleted by centrifugation at 14,000 × g for 10 min at 4°C. Protein concentration was determined by DC Assay (BioRad) and samples were diluted to 1 mg/ml in lysis buffer. Samples were precleared with 5 μl Protein A/G Plus beads (SCBT) for 1 h. FLAG-tagged PAK2 was immunoprecipitated by incubating precleared samples with 10 μl anti-FLAG M2 agarose (Sigma-Aldrich) for 16 h at 4°C. Beads were pelleted at 5000 × g for 30 seconds and washed 4X with lysis buffer. Bound protein was eluted by boiling beads with 2X SDS sample buffer. Samples were subjected to SDS-PAGE (12% polyacrylamide) and transferred to PVDF for Western blotting. Blots were blocked with 5% milk in TBS + 0.05% Tween-20, and then probed with HA-HRP (1:500, Roche), FLAG-HRP (1:500, Sigma), anti-β-tubulin (1:1000, Sigma-Aldrich) and anti-CDC42 (SCBT, 1:200).
We thank Etienne Gagnon, Kristin Agopian, Vikas Misra, Megan Mefford, and Edana Cassol for advice and discussions, Hillel Haim and Joseph Sodroski for providing the HXB2 Env plasmids, Andreas Baur for providing the pNL4-3 MCS Nef provirus, Damian Purcell for providing the pNL4-3 ΔNef (ΔXhoI) provirus, and Michel Tremblay for providing the IL2-Luc and NFAT-Luc stable cell lines. The following reagent was obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID: MAGI-CCR5 from Dr. Julie Overbaugh. pHAGE was obtained from the Harvard Gene Therapy Initiative plasmid repository. This work was supported by NIH grants R21 AI73415, R21 AI77464, and DP1 DA028994. K.C.O. was supported in part by T32 AI007386. J.M. was supported in part by T32 AG00222. Core facilities were supported by Harvard University Center for AIDS Research and DFCI/Harvard Cancer Center grants.
- Arhel NJ, Kirchhoff F: Implications of Nef: host cell interactions in viral persistence and progression to AIDS. Curr Top Microbiol Immunol. 2009, 339: 147-175. 10.1007/978-3-642-02175-6_8.PubMed
- Gorry PR, McPhee DA, Verity E, Dyer WB, Wesselingh SL, Learmont J, Sullivan JS, Roche M, Zaunders JJ, Gabuzda D, et al: Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology. 2007, 4: 66-10.1186/1742-4690-4-66.PubMed CentralView ArticlePubMed
- Dyer WB, Zaunders JJ, Yuan FF, Wang B, Learmont JC, Geczy AF, Saksena NK, McPhee DA, Gorry PR, Sullivan JS: Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Retrovirology. 2008, 5: 112-10.1186/1742-4690-5-112.PubMed CentralView ArticlePubMed
- Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992, 258 (5090): 1938-1941. 10.1126/science.1470917.View ArticlePubMed
- Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, Weinfurter JT, Kaizu M, Soma T, Leon EJ, MacNair C, et al: Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med. 2008, 205 (11): 2537-2550. 10.1084/jem.20081524.PubMed CentralView ArticlePubMed
- Munch J, Rajan D, Schindler M, Specht A, Rucker E, Novembre FJ, Nerrienet E, Muller-Trutwin MC, Peeters M, Hahn BH, et al: Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol. 2007, 81 (24): 13852-13864. 10.1128/JVI.00904-07.PubMed CentralView ArticlePubMed
- Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, Richman DD: The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med. 1994, 179 (1): 115-123. 10.1084/jem.179.1.115.View ArticlePubMed
- Miller MD, Feinberg MB, Greene WC: The HIV-1 nef gene acts as a positive viral infectivity factor. Trends Microbiol. 1994, 2 (8): 294-298. 10.1016/0966-842X(94)90007-8.View ArticlePubMed
- Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB: The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med. 1994, 179 (1): 101-113. 10.1084/jem.179.1.101.View ArticlePubMed
- Papkalla A, Munch J, Otto C, Kirchhoff F: Nef enhances human immunodeficiency virus type 1 infectivity and replication independently of viral coreceptor tropism. J Virol. 2002, 76 (16): 8455-8459. 10.1128/JVI.76.16.8455-8459.2002.PubMed CentralView ArticlePubMed
- de Ronde A, Klaver B, Keulen W, Smit L, Goudsmit J: Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes. Virology. 1992, 188 (1): 391-395. 10.1016/0042-6822(92)90772-H.View ArticlePubMed
- Arganaraz ER, Schindler M, Kirchhoff F, Cortes MJ, Lama J: Enhanced CD4 down-modulation by late stage HIV-1 nef alleles is associated with increased Env incorporation and viral replication. J Biol Chem. 2003, 278 (36): 33912-33919. 10.1074/jbc.M303679200.View ArticlePubMed
- Lundquist CA, Zhou J, Aiken C: Nef stimulates human immunodeficiency virus type 1 replication in primary T cells by enhancing virion-associated gp120 levels: coreceptor-dependent requirement for Nef in viral replication. J Virol. 2004, 78 (12): 6287-6296. 10.1128/JVI.78.12.6287-6296.2004.PubMed CentralView ArticlePubMed
- Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 1998, 391 (6665): 397-401. 10.1038/34929.View ArticlePubMed
- Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL: HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. PLoS Pathog. 2008, 4 (8): e1000131-10.1371/journal.ppat.1000131.PubMed CentralView ArticlePubMed
- Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA: HIV-1 replication is controlled at the level of T cell activation and proviral integration. Embo J. 1990, 9 (5): 1551-1560.PubMed CentralPubMed
- Unutmaz D, KewalRamani VN, Marmon S, Littman DR: Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J Exp Med. 1999, 189 (11): 1735-1746. 10.1084/jem.189.11.1735.PubMed CentralView ArticlePubMed
- Dai J, Agosto LM, Baytop C, Yu JJ, Pace MJ, Liszewski MK, O'Doherty U: Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J Virol. 2009, 83 (9): 4528-4537. 10.1128/JVI.01910-08.PubMed CentralView ArticlePubMed
- Wu Y, Marsh JW: Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science. 2001, 293 (5534): 1503-1506. 10.1126/science.1061548.View ArticlePubMed
- Manninen A, Huotari P, Hiipakka M, Renkema GH, Saksela K: Activation of NFAT-dependent gene expression by Nef: conservation among divergent Nef alleles, dependence on SH3 binding and membrane association, and cooperation with protein kinase C-theta. J Virol. 2001, 75 (6): 3034-3037. 10.1128/JVI.75.6.3034-3037.2001.PubMed CentralView ArticlePubMed
- Wang JK, Kiyokawa E, Verdin E, Trono D: The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci USA. 2000, 97 (1): 394-399. 10.1073/pnas.97.1.394.PubMed CentralView ArticlePubMed
- Fenard D, Yonemoto W, de Noronha C, Cavrois M, Williams SA, Greene WC: Nef is physically recruited into the immunological synapse and potentiates T cell activation early after TCR engagement. J Immunol. 2005, 175 (9): 6050-6057.View ArticlePubMed
- Fortin JF, Barat C, Beausejour Y, Barbeau B, Tremblay MJ: Hyper-responsiveness to stimulation of human immunodeficiency virus-infected CD4+ T cells requires Nef and Tat virus gene products and results from higher NFAT, NF-kappaB, and AP-1 induction. J Biol Chem. 2004, 279 (38): 39520-39531. 10.1074/jbc.M407477200.View ArticlePubMed
- Schrager JA, Marsh JW: HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc Natl Acad Sci USA. 1999, 96 (14): 8167-8172. 10.1073/pnas.96.14.8167.PubMed CentralView ArticlePubMed
- Schindler M, Munch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Muller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, et al: Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell. 2006, 125 (6): 1055-1067. 10.1016/j.cell.2006.04.033.View ArticlePubMed
- Priceputu E, Hanna Z, Hu C, Simard MC, Vincent P, Wildum S, Schindler M, Kirchhoff F, Jolicoeur P: Primary human immunodeficiency virus type 1 nef alleles show major differences in pathogenicity in transgenic mice. J Virol. 2007, 81 (9): 4677-4693. 10.1128/JVI.02691-06.PubMed CentralView ArticlePubMed
- Arold S, Franken P, Strub MP, Hoh F, Benichou S, Benarous R, Dumas C: The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure. 1997, 5 (10): 1361-1372. 10.1016/S0969-2126(97)00286-4.View ArticlePubMed
- Arold S, O'Brien R, Franken P, Strub MP, Hoh F, Dumas C, Ladbury JE: RT loop flexibility enhances the specificity of Src family SH3 domains for HIV-1 Nef. Biochemistry. 1998, 37 (42): 14683-14691. 10.1021/bi980989q.View ArticlePubMed
- Trible RP, Emert-Sedlak L, Smithgall TE: HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src through direct SH3 domain interaction. J Biol Chem. 2006, 281 (37): 27029-27038. 10.1074/jbc.M601128200.PubMed CentralView ArticlePubMed
- Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R: T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol Rev. 2009, 228 (1): 9-22. 10.1111/j.1600-065X.2008.00745.x.View ArticlePubMed
- Rauch S, Pulkkinen K, Saksela K, Fackler OT: Human immunodeficiency virus type 1 Nef recruits the guanine exchange factor Vav1 via an unexpected interface into plasma membrane microdomains for association with p21-activated kinase 2 activity. J Virol. 2008, 82 (6): 2918-2929. 10.1128/JVI.02185-07.PubMed CentralView ArticlePubMed
- Simmons A, Gangadharan B, Hodges A, Sharrocks K, Prabhakar S, Garcia A, Dwek R, Zitzmann N, McMichael A: Nef-mediated lipid raft exclusion of UbcH7 inhibits Cbl activity in T cells to positively regulate signaling. Immunity. 2005, 23 (6): 621-634. 10.1016/j.immuni.2005.11.003.View ArticlePubMed
- Haller C, Rauch S, Michel N, Hannemann S, Lehmann MJ, Keppler OT, Fackler OT: The HIV-1 pathogenicity factor Nef interferes with maturation of stimulatory T-lymphocyte contacts by modulation of N-Wasp activity. J Biol Chem. 2006, 281 (28): 19618-19630. 10.1074/jbc.M513802200.View ArticlePubMed
- Wei BL, Arora VK, Raney A, Kuo LS, Xiao GH, O'Neill E, Testa JR, Foster JL, Garcia JV: Activation of p21-activated kinase 2 by human immunodeficiency virus type 1 Nef induces merlin phosphorylation. J Virol. 2005, 79 (23): 14976-14980. 10.1128/JVI.79.23.14976-14980.2005.PubMed CentralView ArticlePubMed
- Stolp B, Reichman-Fried M, Abraham L, Pan X, Giese SI, Hannemann S, Goulimari P, Raz E, Grosse R, Fackler OT: HIV-1 Nef interferes with host cell motility by deregulation of Cofilin. Cell Host Microbe. 2009, 6 (2): 174-186. 10.1016/j.chom.2009.06.004.View ArticlePubMed
- Stolp B, Abraham L, Rudolph JM, Fackler OT: Lentiviral Nef proteins utilize PAK2-mediated deregulation of cofilin as a general strategy to interfere with actin remodeling. J Virol. 84 (8): 3935-3948.
- Nunn MF, Marsh JW: Human immunodeficiency virus type 1 Nef associates with a member of the p21-activated kinase family. J Virol. 1996, 70 (9): 6157-6161.PubMed CentralPubMed
- Renkema GH, Manninen A, Mann DA, Harris M, Saksela K: Identification of the Nef-associated kinase as p21-activated kinase 2. Curr Biol. 1999, 9 (23): 1407-1410. 10.1016/S0960-9822(00)80086-X.View ArticlePubMed
- Arora VK, Molina RP, Foster JL, Blakemore JL, Chernoff J, Fredericksen BL, Garcia JV: Lentivirus Nef specifically activates Pak2. J Virol. 2000, 74 (23): 11081-11087. 10.1128/JVI.74.23.11081-11087.2000.PubMed CentralView ArticlePubMed
- Krautkramer E, Giese SI, Gasteier JE, Muranyi W, Fackler OT: Human immunodeficiency virus type 1 Nef activates p21-activated kinase via recruitment into lipid rafts. J Virol. 2004, 78 (8): 4085-4097. 10.1128/JVI.78.8.4085-4097.2004.PubMed CentralView ArticlePubMed
- Pulkkinen K, Renkema GH, Kirchhoff F, Saksela K: Nef associates with p21-activated kinase 2 in a p21-GTPase-dependent dynamic activation complex within lipid rafts. J Virol. 2004, 78 (23): 12773-12780. 10.1128/JVI.78.23.12773-12780.2004.PubMed CentralView ArticlePubMed
- Raney A, Kuo LS, Baugh LL, Foster JL, Garcia JV: Reconstitution and molecular analysis of an active human immunodeficiency virus type 1 Nef/p21-activated kinase 2 complex. J Virol. 2005, 79 (20): 12732-12741. 10.1128/JVI.79.20.12732-12741.2005.PubMed CentralView ArticlePubMed
- Renkema GH, Manninen A, Saksela K: Human immunodeficiency virus type 1 Nef selectively associates with a catalytically active subpopulation of p21-activated kinase 2 (PAK2) independently of PAK2 binding to Nck or beta-PIX. J Virol. 2001, 75 (5): 2154-2160. 10.1128/JVI.75.5.2154-2160.2001.PubMed CentralView ArticlePubMed
- Manninen A, Hiipakka M, Vihinen M, Lu W, Mayer BJ, Saksela K: SH3-Domain binding function of HIV-1 Nef is required for association with a PAK-related kinase. Virology. 1998, 250 (2): 273-282. 10.1006/viro.1998.9381.View ArticlePubMed
- Khan IH, Sawai ET, Antonio E, Weber CJ, Mandell CP, Montbriand P, Luciw PA: Role of the SH3-ligand domain of simian immunodeficiency virus Nef in interaction with Nef-associated kinase and simian AIDS in rhesus macaques. J Virol. 1998, 72 (7): 5820-5830.PubMed CentralPubMed
- Fackler OT, Wolf D, Weber HO, Laffert B, D'Aloja P, Schuler-Thurner B, Geffin R, Saksela K, Geyer M, Peterlin BM, et al: A natural variability in the proline-rich motif of Nef modulates HIV-1 replication in primary T cells. Curr Biol. 2001, 11 (16): 1294-1299. 10.1016/S0960-9822(01)00373-6.View ArticlePubMed
- Brown A, Moghaddam S, Kawano T, Cheng-Mayer C: Multiple human immunodeficiency virus type 1 Nef functions contribute to efficient replication in primary human macrophages. J Gen Virol. 2004, 85 (Pt 6): 1463-1469.View ArticlePubMed
- Agopian K, Wei BL, Garcia JV, Gabuzda D: A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2. J Virol. 2006, 80 (6): 3050-3061. 10.1128/JVI.80.6.3050-3061.2006.PubMed CentralView ArticlePubMed
- O'Neill E, Kuo LS, Krisko JF, Tomchick DR, Garcia JV, Foster JL: Dynamic evolution of the human immunodeficiency virus type 1 pathogenic factor, Nef. J Virol. 2006, 80 (3): 1311-1320. 10.1128/JVI.80.3.1311-1320.2006.PubMed CentralView ArticlePubMed
- O'Neill E, Baugh LL, Novitsky VA, Essex ME, Garcia JV: Intra- and intersubtype alternative Pak2-activating structural motifs of human immunodeficiency virus type 1 Nef. J Virol. 2006, 80 (17): 8824-8829. 10.1128/JVI.00910-06.PubMed CentralView ArticlePubMed
- Trible RP, Emert-Sedlak L, Wales TE, Ayyavoo V, Engen JR, Smithgall TE: Allosteric loss-of-function mutations in HIV-1 Nef from a long-term non-progressor. J Mol Biol. 2007, 374 (1): 121-129. 10.1016/j.jmb.2007.09.009.PubMed CentralView ArticlePubMed
- Schindler M, Rajan D, Specht A, Ritter C, Pulkkinen K, Saksela K, Kirchhoff F: Association of Nef with p21-activated kinase 2 is dispensable for efficient human immunodeficiency virus type 1 replication and cytopathicity in ex vivo-infected human lymphoid tissue. J Virol. 2007, 81 (23): 13005-13014. 10.1128/JVI.01436-07.PubMed CentralView ArticlePubMed
- Renkema GH, Saksela K: Interactions of HIV-1 NEF with cellular signal transducing proteins. Front Biosci. 2000, 5: D268-283. 10.2741/Renkema.View ArticlePubMed
- Saksela K, Cheng G, Baltimore D: Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. Embo J. 1995, 14 (3): 484-491.PubMed CentralPubMed
- Adachi A, Koenig S, Gendelman HE, Daugherty D, Gattoni-Celli S, Fauci AS, Martin MA: Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J Virol. 1987, 61 (1): 209-213.PubMed CentralPubMed
- Aiken C, Trono D: Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol. 1995, 69 (8): 5048-5056.PubMed CentralPubMed
- Luo T, Livingston RA, Garcia JV: Infectivity enhancement by human immunodeficiency virus type 1 Nef is independent of its association with a cellular serine/threonine kinase. J Virol. 1997, 71 (12): 9524-9530.PubMed CentralPubMed
- Katchar K, Wahlstrom J, Eklund A, Grunewald J: Highly activated T-cell receptor AV2S3(+) CD4(+) lung T-cell expansions in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2001, 163 (7): 1540-1545.View ArticlePubMed
- Simmons A, Aluvihare V, McMichael A: Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity. 2001, 14 (6): 763-777. 10.1016/S1074-7613(01)00158-3.View ArticlePubMed
- Schibeci SD, Clegg AO, Biti RA, Sagawa K, Stewart GJ, Williamson P: HIV-Nef enhances interleukin-2 production and phosphatidylinositol 3-kinase activity in a human T cell line. Aids. 2000, 14 (12): 1701-1707. 10.1097/00002030-200008180-00003.View ArticlePubMed
- Chazal N, Singer G, Aiken C, Hammarskjold ML, Rekosh D: Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J Virol. 2001, 75 (8): 4014-4018. 10.1128/JVI.75.8.4014-4018.2001.PubMed CentralView ArticlePubMed
- Chu P, Pardo J, Zhao H, Li CC, Pali E, Shen MM, Qu K, Yu SX, Huang BC, Yu P, et al: Systematic identification of regulatory proteins critical for T-cell activation. J Biol. 2003, 2 (3): 21-10.1186/1475-4924-2-21.PubMed CentralView ArticlePubMed
- Chu PC, Wu J, Liao XC, Pardo J, Zhao H, Li C, Mendenhall MK, Pali E, Shen M, Yu S, et al: A novel role for p21-activated protein kinase 2 in T cell activation. J Immunol. 2004, 172 (12): 7324-7334.View ArticlePubMed
- Cavalieri S, Cazzaniga S, Geuna M, Magnani Z, Bordignon C, Naldini L, Bonini C: Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood. 2003, 102 (2): 497-505. 10.1182/blood-2003-01-0297.View ArticlePubMed
- Swingler S, Mann A, Jacque J, Brichacek B, Sasseville VG, Williams K, Lackner AA, Janoff EN, Wang R, Fisher D, et al: HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med. 1999, 5 (9): 997-103. 10.1038/12433.View ArticlePubMed
- Nguyen DG, Wolff KC, Yin H, Caldwell JS, Kuhen KL: "UnPAKing" human immunodeficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection. J Virol. 2006, 80 (1): 130-137. 10.1128/JVI.80.1.130-137.2006.PubMed CentralView ArticlePubMed
- Sawai ET, Khan IH, Montbriand PM, Peterlin BM, Cheng-Mayer C, Luciw PA: Activation of PAK by HIV and SIV Nef: importance for AIDS in rhesus macaques. Curr Biol. 1996, 6 (11): 1519-1527. 10.1016/S0960-9822(96)00757-9.View ArticlePubMed
- Carl S, Iafrate AJ, Lang SM, Stolte N, Stahl-Hennig C, Matz-Rensing K, Fuchs D, Skowronski J, Kirchhoff F: Simian immunodeficiency virus containing mutations in N-terminal tyrosine residues and in the PxxP motif in Nef replicates efficiently in rhesus macaques. J Virol. 2000, 74 (9): 4155-4164. 10.1128/JVI.74.9.4155-4164.2000.PubMed CentralView ArticlePubMed
- Olivieri KC, Agopian KA, Mukerji J, Gabuzda D: Evidence for adaptive evolution at the divergence between lymphoid and brain HIV-1 nef genes. AIDS Res Hum Retroviruses. 26 (4): 495-500.
- Crotti A, Neri F, Corti D, Ghezzi S, Heltai S, Baur A, Poli G, Santagostino E, Vicenzi E: Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation. J Virol. 2006, 80 (21): 10663-10674. 10.1128/JVI.02621-05.PubMed CentralView ArticlePubMed
- Rho HM, Poiesz B, Ruscetti FW, Gallo RC: Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology. 1981, 112 (1): 355-360. 10.1016/0042-6822(81)90642-5.View ArticlePubMed
- Wilson AA, Kwok LW, Hovav AH, Ohle SJ, Little FF, Fine A, Kotton DN: Sustained expression of alpha1-antitrypsin after transplantation of manipulated hematopoietic stem cells. Am J Respir Cell Mol Biol. 2008, 39 (2): 133-141. 10.1165/rcmb.2007-0133OC.PubMed CentralView ArticlePubMed
- Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 1997, 15 (9): 871-875. 10.1038/nbt0997-871.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.